KAYO 2000
Alternative Names: KAYO-2000Latest Information Update: 31 Mar 2025
At a glance
- Originator KayoThera
- Class Obesity therapies
- Mechanism of Action Retinoid X receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 24 Mar 2025 Preclinical trials in Obesity in USA (PO) (KayoThera pipeline, March 2025)